Literature DB >> 6755024

Changes in human adenovirus 5 propagated in Burkitt's lymphoma cells.

N Faucon, G Ogier, Y Chardonnet.   

Abstract

The effect of host cells on human adenovirus 5 properties was studied with the use of Burkitt's lymphoma cell lines (Raji and Jijoye) that poorly replicate the virus. Only a small fraction of the cell population was producing adenovirus 5. The major virus components were synthesized; however, the purified virus particles differed from those produced in HeLa cells by lower density in CsCl gradient, lower content in DNA, limited changes in DNA restriction enzyme pattern, and polypeptide composition. After one passage in HeLa cells, modifications of polypeptides reversed.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6755024

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  5 in total

1.  Nonpermissivity of human peripheral blood lymphocytes to adenovirus type 2 infection.

Authors:  J Horvath; J M Weber
Journal:  J Virol       Date:  1988-01       Impact factor: 5.103

2.  Adenovirus types 11p and 35p show high binding efficiencies for committed hematopoietic cell lines and are infective to these cell lines.

Authors:  A Segerman; Y F Mei; G Wadell
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

3.  Functional and selective targeting of adenovirus to high-affinity Fcgamma receptor I-positive cells by using a bispecific hybrid adapter.

Authors:  C Ebbinghaus; A Al-Jaibaji; E Operschall; A Schöffel; I Peter; U F Greber; S Hemmi
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

4.  Inhibition of type 5 adenovirus infectivity by periodate oxidation.

Authors:  G Ogier; Y Michal; V Thomas; G Quash; J D Rodwell
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

5.  Group C adenovirus DNA sequences in human lymphoid cells.

Authors:  J Horvath; L Palkonyay; J Weber
Journal:  J Virol       Date:  1986-07       Impact factor: 5.103

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.